GALECTIN THERAPEUTICS INC

# Galectin Therapeutics Inc.

Based in Norcross, Georgia, Galectin Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies targeting fibrotic and oncologic diseases. The company's primary asset is belapectin (GR-MD-02), a galectin-3 inhibitor currently undergoing clinical evaluation across multiple indications. Belapectin is in Phase 2b/3 trials for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis cirrhosis and Phase 2 trials for liver fibrosis, severe skin disease, melanoma, and head and neck squamous cell carcinoma.

The company operates through collaborative arrangements with research partners, including a joint venture with SBH Sciences, Inc. and Galectin Sciences, LLC that focuses on developing oral small molecule galectin-3 inhibitors. As a clinical-stage entity, Galectin Therapeutics has not disclosed significant revenue generation from product sales. The company operates with a lean organizational structure of approximately 15 full-time employees and maintains headquarters in Georgia with Nasdaq listing status. The company was founded in 2000 and previously operated under the name Pro-Pharmaceuticals, Inc. before rebranding in 2011.